Lymphovascular space invasion as a prognostic factor of epithelial ovarian cancer: a multicenter study by the FRANCOGYN group.
Lymphovascular space invasion
Ovarian cancer
Overall Survival
Prognosis
Recurrence-Free Survival
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
11
11
2020
accepted:
28
05
2021
pubmed:
30
6
2021
medline:
26
11
2021
entrez:
29
6
2021
Statut:
ppublish
Résumé
The presence of lymphovascular space invasion (LVSI) is not yet included in international recommendations neither as a prognostic factor nor as a parameter for the decision to use adjuvant chemotherapy in FIGO stage I/IIa ovarian cancer (OC). This study set out to evaluate the impact of LVSI on Overall Survival (OS) and Recurrence-Free Survival (RFS) in patients managed for epithelial OC. Retrospective multicenter study by the research group FRANCOGYN between January 2001 and December 2018. All patients managed for epithelial OC surgery and for whom histological slides for the review of LVSI were available, were included. The characteristics of patients with LVSI (LVSI group) were compared to those without LVSI (No-LVSI group). A Cox analysis for OS and RFS analysis was performed in all the populations. French multicenter tertiary care centers RESULTS: Over the study period, 852 patients were included in the 13 institutions. Among them, 289 patients had LVSI (33.9%). There was a significant difference in the distribution of LVSI between early and advanced stages (p < 0.001). LVSI was an independent predictive factor for poorer Overall and Recurrence-Free Survival. LVSI affected OS (p < 0.001) and RFS (p < 0.001), LVSI affected OS and RFS for early stages (p = 0.001; p = 0.001, respectively) and also for advanced stages (p = 0.01; p = 0.009, respectively). The presence of LVSI in epithelial ovarian epithelial tumors has an impact on OS and RFS and should be included in the routine pathology examination to adapt therapeutic management, especially for women in the early stages of the disease.
Sections du résumé
BACKGROUND
The presence of lymphovascular space invasion (LVSI) is not yet included in international recommendations neither as a prognostic factor nor as a parameter for the decision to use adjuvant chemotherapy in FIGO stage I/IIa ovarian cancer (OC).
OBJECTIVE
This study set out to evaluate the impact of LVSI on Overall Survival (OS) and Recurrence-Free Survival (RFS) in patients managed for epithelial OC.
DESIGN
Retrospective multicenter study by the research group FRANCOGYN between January 2001 and December 2018. All patients managed for epithelial OC surgery and for whom histological slides for the review of LVSI were available, were included. The characteristics of patients with LVSI (LVSI group) were compared to those without LVSI (No-LVSI group). A Cox analysis for OS and RFS analysis was performed in all the populations.
SETTING
French multicenter tertiary care centers RESULTS: Over the study period, 852 patients were included in the 13 institutions. Among them, 289 patients had LVSI (33.9%). There was a significant difference in the distribution of LVSI between early and advanced stages (p < 0.001). LVSI was an independent predictive factor for poorer Overall and Recurrence-Free Survival. LVSI affected OS (p < 0.001) and RFS (p < 0.001), LVSI affected OS and RFS for early stages (p = 0.001; p = 0.001, respectively) and also for advanced stages (p = 0.01; p = 0.009, respectively).
CONCLUSION
The presence of LVSI in epithelial ovarian epithelial tumors has an impact on OS and RFS and should be included in the routine pathology examination to adapt therapeutic management, especially for women in the early stages of the disease.
Identifiants
pubmed: 34184114
doi: 10.1007/s00404-021-06110-x
pii: 10.1007/s00404-021-06110-x
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
1577-1585Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492
doi: 10.3322/caac.21492
Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M et al (2017) The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2). Gynecol Oncol 144(2):405–413
doi: 10.1016/j.ygyno.2016.10.019
Wentzensen N, Poole EM, Trabert B, White E, Arslan AA, Patel AV et al (2016) Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. J Clin Oncol 34(24):2888–2898
doi: 10.1200/JCO.2016.66.8178
Reid BM, Permuth JB, Sellers TA (2017) Epidemiology of ovarian cancer: a review. Cancer Biol Med 14(1):9–32
doi: 10.20892/j.issn.2095-3941.2016.0084
Cowppli-Bony A, Uhry Z, Guizard V, Trétarre B, Bouvier AM, Woronoff AS, Grosclaude P (2016) Survie des personnes atteintes de cancers solides en France métropolitaine, 1989–2013. Rev d’Épidémiol Santé Publique 64:S201–S202
doi: 10.1016/j.respe.2016.06.084
Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30
doi: 10.3322/caac.21442
Bowtell DDL (2010) The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10(11):803–808
doi: 10.1038/nrc2946
Obeidat B, Latimer J, Crawford R (2004) Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? role of preoperative serum CA-125 level. Gynecol Obstet Invest 57(3):153–156
doi: 10.1159/000076236
Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC et al (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353(8):793–802
doi: 10.1056/NEJMoa050434
dos Reis R, Burzawa JK, Tsunoda AT, Hosaka M, Frumovitz M, Westin SN et al (2015) Lymphovascular space invasion portends poor prognosis in low-risk endometrial cancer. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 25(7):1292–1299
doi: 10.1097/IGC.0000000000000490
Lim CS, Alexander-Sefre F, Allam M, Singh N, Aleong JC, Al-Rawi H et al (2008) Clinical value of immunohistochemically detected lymphovascular space invasion in early stage cervical carcinoma. Ann Surg Oncol 15(9):2581–2588
doi: 10.1245/s10434-008-0014-z
Cohen SJ, Punt CJA, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY et al (2008) Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 26(19):3213–3221
doi: 10.1200/JCO.2007.15.8923
Li J, Li S, Chen R, Lu X (2017) Increased risk of poor survival in ovarian cancer patients with high expression of SNAI2 and lymphovascular space invasion. Oncotarget 8(6):9672–9685
doi: 10.18632/oncotarget.14192
Zeng L, Liang X, Liu Q, Yang Z (2017) The predictive value of circulating tumor cells in ovarian cancer: a meta-analysis. Int J Gynecol Cancer 27(6):1109–1117
doi: 10.1097/IGC.0000000000000459
Zhou Y, Bian B, Yuan X, Xie G, Ma Y, Shen L (2015) Prognostic value of circulating tumor cells in ovarian cancer: a meta-analysis. PLoS ONE 10(6):e0130873
doi: 10.1371/journal.pone.0130873
ARCAGY. Disponible sur. https://arcagy.org/arcagy-gineco-organisation-et-recherche/gineco/2396 . Accessed 5 May 2020.
Chay W-Y, Chew S-H, Ong W-S, Busmanis I, Li X, Thung S et al (2013) HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer. PLoS ONE 8(4):e61565
doi: 10.1371/journal.pone.0061565
Matsuo K, Sheridan TB, Mabuchi S, Yoshino K, Hasegawa K, Studeman KD et al (2014) Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. Gynecol Oncol 133(3):473–479
doi: 10.1016/j.ygyno.2014.03.563
Matsuo K, Sheridan TB, Yoshino K, Miyake T, Hew KE, Im DD et al (2012) Significance of lymphovascular space invasion in epithelial ovarian cancer. Cancer Med 1(2):156–164
doi: 10.1002/cam4.31
Chen M, Jin Y, Bi Y, Li Y, Shan Y, Pan L (2015) Prognostic significance of lymphovascular space invasion in epithelial ovarian cancer. J Cancer 6(5):412–419
doi: 10.7150/jca.11242
Spannuth WA, Sood AK, Coleman RL (2008) Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 5(4):194–204
doi: 10.1038/ncponc1051